Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBITDA Margin (2020 - 2025)

Foghorn Therapeutics has reported EBITDA Margin over the past 6 years, most recently at 234.28% for Q4 2025.

  • Quarterly results put EBITDA Margin at 234.28% for Q4 2025, up 45647.0% from a year ago — trailing twelve months through Dec 2025 was 240.69% (up 13830.0% YoY), and the annual figure for FY2025 was 240.69%, up 13830.0%.
  • EBITDA Margin for Q4 2025 was 234.28% at Foghorn Therapeutics, down from 193.56% in the prior quarter.
  • Over the last five years, EBITDA Margin for FHTX hit a ceiling of 77.35% in Q3 2023 and a floor of 63617.07% in Q3 2021.
  • Median EBITDA Margin over the past 5 years was 506.4% (2023), compared with a mean of 4538.18%.
  • Biggest five-year swings in EBITDA Margin: crashed -5335618bps in 2021 and later soared 6320339bps in 2022.
  • Foghorn Therapeutics' EBITDA Margin stood at 4086.96% in 2021, then surged by 84bps to 669.41% in 2022, then skyrocketed by 40bps to 399.36% in 2023, then crashed by -73bps to 690.76% in 2024, then skyrocketed by 66bps to 234.28% in 2025.
  • The last three reported values for EBITDA Margin were 234.28% (Q4 2025), 193.56% (Q3 2025), and 238.11% (Q2 2025) per Business Quant data.